Celcuity Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon and welcome to day 2 of the annual Needham & Company healthcare conference. My name is Gil Blum, and I'm a senior biotech analyst here at Needham & Company, covering the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Brian Sullivan, CEO of Celcuity. (Conference Instructions)
And with that, Brian, you have the stage.
Great. Well, [thank you, Gil.] Thank you for those of you who are listening. I look forward to introducing you to Celcuity. I started the company with our Chief Science Officer number of years ago with the goal of developing a new method of identifying disease drivers. I'm sure you all are familiar with genetic testing and the role they've played in being able to help select more precisely patients who might be responsive to targeted therapies.
Our goal is to improve on that by identifying patients who might respond to a targeted therapy even though they lacked a targeted
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |